Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-136P** is classified as a **pseudogene** of the U6 small nuclear RNA family. Pseudogenes are non-coding DNA sequences resembling functional genes but typically lack protein-coding potential and are not transcribed into functional RNA or proteins. The functional U6 small nuclear RNA (snRNA) is a crucial, highly conserved component of the spliceosome, the ribonucleoprotein complex responsible for pre-mRNA splicing in eukaryotes[3][1]. However, RNU6-136P itself is instead a retrotransposed, non-functional remnant and does not participate in splicing or other biological processes[4][5]. Its presence is an evolutionary marker of genomic retrotransposition dynamics but does not have a known direct biological function or disease role, and it is not considered a druggable or therapeutic target[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 136, pseudogene (RNU6-136P).